Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit
Cosmos Health (NASDAQ:COSM) reported over $1.5 million in combined annualized sales for its C-Scrub and C-Sept antiseptic brands across the UK and Greece, with gross margins above 70%.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported over $1.5 million in combined annualized sales for its C-Scrub and C-Sept antiseptic brands across the UK and Greece, with gross margins above 70%.
The company targets 2028 revenue of $7.4 million and gross profit of $5.3 million via EU expansion and animal healthcare.
Positive
- C-Scrub and C-Sept exceed $1.5 million in annualized sales in UK and Greece
- Gross margins above 70%, with targets implying approximately 72% over three years
- Three-year targets: revenue to $2.5M (2026), $4.2M (2027), $7.4M (2028)
- Three-year gross profit targets: $1.8M (2026), $3.0M (2027), $5.3M (2028)
- Planned expansion into additional EU countries and animal healthcare markets for C-Scrub
Negative
- None.
Details
News Market Reaction – COSM
On Jun 12, the day this news came out, COSM closed 1.94% above the previous close.
Data tracked by StockTitan Argus for the Jun 12 session.
Key Figures
- Annualized sales
- Over $1.5M
- Combined trailing‑twelve‑month sales for C‑Scrub and C‑Sept in UK and Greece
- Gross margin
- Above 70%
- C‑Scrub and C‑Sept margin profile in initial markets
- 2026 revenue target
- $2.5M
- Projected 2026 C‑Scrub/C‑Sept revenue
- 2026 gross profit
- $1.8M
- Projected 2026 C‑Scrub/C‑Sept gross profit
- 2027 revenue target
- $4.2M
- Projected 2027 C‑Scrub/C‑Sept revenue
- 2027 gross profit
- $3.0M
- Projected 2027 C‑Scrub/C‑Sept gross profit
- 2028 revenue target
- $7.4M
- Projected 2028 C‑Scrub/C‑Sept revenue
- 2028 gross profit
- $5.3M
- Projected 2028 C‑Scrub/C‑Sept gross profit
Previous Crypto Reports
-
Extra 180 days granted to regain Nasdaq $1.00 minimum bid compliance.
-
Three‑year deal to make 3.9M VASCLOR GEST progesterone pessary units.
-
Launch of capsule line plus five‑year CERTORUN contract for 385,000 units.
-
U.S. launch of Oliv18 nutraceutical targeting cardiovascular and antioxidant markets.
-
Sky Premium Life made shippable across all 27 EU states via Skroutz.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Strong sales momentum: across the UK and Greece, the brands' first two markets.
- Over
$1.5 million in sales: C-Scrub and C-Sept have generated over$1.5 million in combined annualized sales across the United Kingdom and Greece. - High-margin proprietary pillar: gross margins above
70% , among the most attractive in Cosmos Health's portfolio. - EU expansion: targeting annual revenue rising to
$7.4 million with gross profit of approximately$5.3 million within three years. - Potential upside: the target may be revised upward as C-Scrub launches into the animal healthcare market.
CHICAGO, June 12, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced strong sales momentum for its proprietary antiseptic brands, C-Scrub and C-Sept, across the United Kingdom and Greece, and outlined a three-year growth target supported by continued momentum and expansion into additional EU markets.
C-Scrub and C-Sept have together generated more than
Nearly half of these sales come from the United Kingdom, with C-Scrub attracting close to 900 ratings on Amazon, the vast majority of which are 5-star, and also available through the e-commerce platforms of Tesco and Superdrug. In Greece, the brands have built strong momentum through the hospital channel, reflecting solid demand and growing adoption among healthcare professionals and consumers.
Based on momentum in the United Kingdom and Greece — the brands’ first two markets — Cosmos Health is targeting the following three-year growth for C-Scrub and C-Sept, supported by continued expansion in both markets and entry into additional EU countries:
- 2026: revenue of approximately
$2.5 million and gross profit of approximately$1.8 million ; - 2027: revenue of approximately
$4.2 million and gross profit of approximately$3.0 million ; - 2028: revenue of approximately
$7.4 million and gross profit of approximately$5.3 million .
These targets reflect gross margins of approximately
Greg Siokas, CEO of Cosmos Health, stated: "We are building a high-margin antiseptics business with C-Scrub and C-Sept, in an area where demand is strong and where we have significant competitive advantages. With over
C-Scrub and C-Sept are proprietary antiseptic products designed to support effective skin cleansing, antimicrobial protection, and professional hygiene across healthcare, clinical, consumer, and animal healthcare settings.
The targets herein represent the Company's current expectations based on current sales trends and anticipated market and channel expansion. Sales figures have been converted into U.S. dollars from British pounds sterling and euros at applicable exchange rates as of the date of this press release. There can be no assurance that the brands will achieve the targets or margins described.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.